Vaccine Pipeline & Products

Dengue

Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. TAK-003 is currently in Phase 3 development and being investigated for the prevention of dengue.

COVID-19

Takeda partnered with the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) and global vaccine developers to rapidly and sustainably supply COVID-19 vaccines in Japan.

Nuvaxovid Intramuscular Injection: Manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine in Japan.
Spikevax Intramuscular Injection: Importation and distribution of Moderna’s COVID-19 vaccine, mRNA-1273, to Japan.

Zika

Takeda’s Zika vaccine candidate (TAK-426) is an inactivated, adjuvanted, whole Zika virus vaccine and will begin Phase 2 development in mid-CY2022. TAK-426 is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Pandemic Influenza

Takeda’s vaccine (BLB-750) is an injectable, whole virion, cell culture-based pandemic influenza vaccine to protect against H5N1. BLB-750 was approved (1mL vials) in Japan in 2014 followed by new formulations (5mL multi dose vials and 0.5mL pre-filled syringes) approved in 2018.

Other Partnered Vaccines

HIL-214: Norovirus vaccine candidate (formerly TAK-214).

Japan Marketed Vaccines

COVID-19
- Nuvaxovid Intramuscular Injection
- Spikevax Intramuscular Injection
BLB-750 (H5N1 Flu)
Measles Rubella*
Mumps
Diphtheria Tetanus Toxoid⁺
Egg-based Seasonal Flu (Denka)
Varicella^ϒ (Biken)
Japanese Encephalitis (Biken)

* Takeda has a measles-rubella combined vaccine, a measles vaccine and a rubella vaccine on the Japanese market.

⁺ Takeda has a diphtheria-tetanus combined vaccine and a tetanus-toxoid vaccine on the Japanese market.

ϒ Takeda’s varicella vaccine has been approved for an additional indication treating herpes-zoster.